Virtual AML Hub Satellite Symposium
During the virtual AML Hub Satellite Symposium, an international panel of five experts will discuss the advantages and challenges of using measurable residual disease (MRD) for prognosis and treatment decisions in patients with acute myeloid leukemia (AML) eligible for stem cell transplantation.
With the recent European LeukemiaNet Working Party guidelines, a standardized approach to MRD assessment in AML has become more feasible for clinical practice. The aim of this virtual symposium is to explore the benefits and limitations of current MRD assessments in order to make treatment teams familiar with MRD measurements in the context of stem cell transplantation.
How does MRD impact outcome of stem cell transplantation in AML – now and in the future?
Sunday August 30, 2020 | 08:30 A.M. CEST
Welcome and introductions
Challenges in MRD measurement by multiparameter flow cytometry in AML
New developments in molecular MRD assessment in AML
Does current evidence support the use of MRD-guided treatment before transplant in patients with AML?
Why should we use MRD assessment post hematopoietic stem cell transplantation?
Round table discussion and Q&A: Use of MRD-guided treatment decisions before and after transplantation
Summary and conclusions: Establishing MRD as a surrogate endpoint in AML, and what does the future hold?